Erlotinib in Treating Patients With Barrett Esophagus

Status unconfirmed · Phase 1

Conditions studied: Esophageal Cancer, Precancerous Condition

In brief

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with Barrett esophagus.

Key facts

Study ID

NCT00566800

Run by

Kansas City Veteran Affairs Medical Center

People needed

25

Starts

2007-07-01

Last updated by the study team

2013-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Veterans Affairs Medical Center - Kansas City — Kansas City, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.